<DOC>
	<DOCNO>NCT01741545</DOCNO>
	<brief_summary>The primary objective study evaluate proportion subject achieve SVR12 ( HCV RNA &lt; LLOQ ( target detect ) post-treatment follow-up Week 12 subject Genotype ( GT ) -1b , -4 GT-2 , -3</brief_summary>
	<brief_title>Safety Efficacy Study Subjects With Chronic HCV Underlying Hemophilia</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . Severe hemophilia ( define &lt; 1 % factor activity level ) Infection hepatitis C virus ( HCV ) underlie hemophilia Males 18 year age Have previously treat interferon Not infect hepatitis B virus ( HBV ) human immunodeficiency virus ( HIV ) Chronic liver disease cause disease chronic HCV infection Presence Bethesda inhibitor Current evidence history portal hypertension</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>